临床试验/NCT07627568

NCT07627568招募中不适用

Analysis of Biomarkers in Patients With Acute Myeloid Leukemia After Allogeneic Stem Cell Transplantation Treated With Menin Inhibition.

University of Freiburg1 个研究点分布在 1 个国家目标入组 20 人开始时间: 2026年5月30日最近更新: 2026年6月10日

适应症

试验速览

阶段: 不适用
状态: 招募中
发起方: University of Freiburg
入组人数: 20
试验地点: 1

研究概览研究设计入排标准研究组 & 干预措施研究者研究点记录与标识符相似试验

研究概览

简要总结

The white blood cells of patients with acute myeloid leukemia that have undergone allogeneic stem cell transplantation will be investigated. These are patient where the leukemia has returned after the transplantation.

详细描述

The study will investigate biomarkers including humen endogenous retrovirus expression and T cell phenotypic analysis in patients with AML with NPM1 mutations or KMT2A rearrangements. These biomarkers have been previously described: Blood. 2026 Jan 29;147(5):584-601. doi: 10.1182/blood.2025029712. PMID: 41144759

研究设计

研究类型: Observational
观察模型: Cohort
时间视角: Prospective

入排标准

年龄范围: 18 Years 至 —（Adult, Older Adult）
性别: All
接受健康志愿者: 否

入选标准

•Diagnosis of acute myeloid leukemia with NPM1 mutations or KMT2A rearrangements
•Hematological relapse after allo-HCT
•18 years or older

排除标准

•no signed informed consent

研究组 & 干预措施

AML with NPM1 mutations or KMT2A rearrangements

AML with NPM1 mutations or KMT2A rearrangements that will be treated with immunotherapy (DLI) and immunmodulatory drugs recommended by the guidelines.

研究者

发起方

University of Freiburg

申办方类型

Other

责任方

Principal Investigator

主要研究者

Robert Zeiser

Professor of Medicine

University of Freiburg

研究点 (1)

Loading locations...

相似试验

尚未招募

不适用

Clinico-hematological and Coagulation Profiles in Newly Diagnosed Acute Myeloid Leukemia Patients Treated With Intensive Induction Chemotherapy .Acute Myeloid Leukemia

NCT07343687Assiut University80

已完成

不适用

Mesenchymal Stem Cells in NPM1 Mutated Low Risk Acute Myeloid Leukemia: a Study of the Tumor Microenvironment and Its Contribution to the Outcome

NCT07379528Fondazione IRCCS Policlinico San Matteo di Pavia70

招募中

1 期

Efficacy and Safety of Autologous Peptide-induced Active Immunity in AML Maintenance TherapyPersonalized Active ImmunotherapyMaintenance TherapyAcute Myeloid Leukemia

NCT07551037Fujian Medical University Union Hospital90

Unknown

不适用

请于伦理委员会批准后才开始征募参试者，并与我们联系上传伦理批件。造血免疫功能状态与急性髓系白血病预后相关性的研究急性髓系白血病

ChiCTR2100045808自筹60

Unknown

不适用

CLL-1 嵌合抗原受体 T 细胞治疗急性髓系白血病的研发

ChiCTR2500100811河南省中青年卫生健康科技创新优青人才培养项目